Skip to main content

Table 2 Treatment-related adverse events by pyrotinib combined with apatinib

From: Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)

Event Patients (N = 33)
Any grade, n (%) Grade 3, n (%)
Diarrhea 30 (90.9) 1 (3.0)
Hypertension 24 (72.7) 3 (9.1)
Anorexia 18 (54.5) 0 (0.0)
Nausea 17 (51.5) 0 (0.0)
Oral mucositis 15 (45.5) 0 (0.0)
Erythra 13 (39.4) 0 (0.0)
Vomiting 10 (30.3) 0 (0.0)
Hand-foot syndrome 9 (27.3) 0 (0.0)
Abdominal pain 7 (21.2) 0 (0.0)
Blood creatinine increased 6 (18.2) 0 (0.0)
Thrombocytopenia 4 (12.1) 0 (0.0)
Anemia 3 (9.1) 0 (0.0)
ALT increased 3 (9.1) 0 (0.0)
AST increased 3 (9.1) 0 (0.0)
Paronychia 3 (9.1) 0 (0.0)
Leukopenia 2 (6.1) 0 (0.0)
Proteinuria 2 (6.1) 0 (0.0)
  1. ALT Alanine aminotransferase, AST Aspartate aminotransferase